Compare TORM plc (TRMD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs Twist Bioscience Corp — how do they compare? TORM plc trades at $39.91 (market cap $4.04B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 2.6× TORM plc's market cap, and TORM plc pays a 11.36% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold TORM plc for 23 Days and Twist Bioscience Corp for 27 Days on average.
| TRMD | TWST | |
|---|---|---|
Market Cap | $4.04B | $10.32B |
Volume | 2,225,810 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $41.05 | $205.00 |
52-Week Low | $19.39 | $25.45 |
Typical Hold Time | 23 Days | 27 Days |
Enterprise Value | $4.75B | $10.24B |
Dividend Yield | 11.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $38.92, down 0.33% on the day, with strong profitability metrics including 35.52% net income margin and 26.84% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent earnings showed mixed results with Q2 2026 missing expectations, while analyst consensus remains unanimously bullish with 100% buy ratings. The company maintains robust cash flow generation with $710M operating cash flow projected for 2026.
TRMD presents attractive valuation with P/E of 6.4 and EV/EBITDA of 5.11, supported by strong dividend yield from upcoming $2.40 payment. Key risks include spot rate volatility in tanker markets and recent insider selling activity. The fundamental outlook remains positive given projected revenue growth to $1.8B in 2026, though investors should monitor freight rate trends and competitive pressures in the product tanker sector.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
